deltatrials
Completed PHASE1 NCT00614978

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer

Sponsor: GlaxoSmithKline

Conditions Brain Metastases HER2 Positive Metastatic Breast Cancer
Interventions lapatinib and temozolomide
Updated 5 times since 2017 Last updated: Sep 18, 2012 Started: Jan 31, 2008 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

Listed as NCT00614978, this PHASE1 trial focuses on Brain Metastases and HER2 Positive and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Jules Bordet Institute
  • Schering-Plough
Data source: Jules Bordet Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Brussels, Belgium